China’s Legend Biotech Corporation (NASDAQ: LEGN) has entered into a strategic platform license (SPL) agreement with US-based cell-engineering company MaxCyte Inc., (NASDAQ: MXCT). The agreement grants Legend Bio a non-exclusive worldwide license to leverage MaxCyte’s Flow Electroporation technology and ExPERT platform. This access will facilitate Legend Bio’s research, clinical development, and commercialization efforts in the realm of cell-based therapeutic products.
In accordance with the deal, MaxCyte stands to receive annual licensing fees and milestone payments from Legend Bio during the clinical development phase. Furthermore, upon any future products achieving market approval, MaxCyte is set to earn licensing fees and royalties based on net sales.
MaxCyte, renowned for its enabling platform technologies, plays a pivotal role in the advancement of next-generation cell-based therapeutics and innovative bioprocessing applications. Notably, MaxCyte was instrumental in the discovery of Casgevy (exagamglogene autotemcel), the pioneering therapy that integrates electroporation with CRISPR/Cas9 gene editing technology. The therapy has garnered significant attention following its initial market approvals in the UK and US by Vertex Pharmaceuticals last year.- Flcube.com
